Nanotechnology Now - Press Release: "AMAG Pharmaceuticals, Inc. to Host Conference Call on April 25, 2008 to Discuss Financial Results for the Quarter Ended March 31, 2008"

Home > Press > AMAG Pharmaceuticals, Inc. to Host Conference Call on April 25, 2008 to Discuss Financial Results for the Quarter Ended March 31, 2008

Abstract:
AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced it will report unaudited consolidated financial results for the quarter ended March 31, 2008 before the U.S. financial markets open on Friday, April 25, 2008. The announcement will be followed by a conference call at 8:00 a.m. ET during which management will discuss the Company's financial results, business highlights and its development programs.

AMAG Pharmaceuticals, Inc. to Host Conference Call on April 25, 2008 to Discuss Financial Results for the Quarter Ended March 31, 2008

Cambridge, MA | Posted on April 19th, 2008

To access the conference call via telephone, please dial (877) 412-6083 from the United States or (706) 902-1303 for international access. A telephone replay will be available from approximately 11:00 a.m. ET on April 25, 2008 through midnight April 29, 2008. To access a replay of the conference call, dial (800) 642-1687 from the United States or (706) 645-9291 for international access. The passcode for the live call and replay is 43018810.

An audio webcast of the call will be available through the Investors section of the Company's website at www.amagpharma.com. The webcast replay will be available from approximately 11:00 a.m. ET on April 25, 2008 through midnight May 25, 2008.

####

About AMAG Pharmaceuticals, Inc.
AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol, the Company’s key product candidate, is being developed for use as an intravenous iron replacement therapeutic for the treatment of iron deficiency anemia in chronic kidney disease patients. The Company has released data on all four planned Phase III clinical trials of ferumoxytol as an intravenous iron replacement therapeutic in chronic kidney disease patients. The Company submitted a New Drug Application for marketing approval of ferumoxytol with the U.S. Food and Drug Administration (FDA) in December 2007, which was accepted for filing by the FDA in February 2008.

For more information, please click here

Contacts:
AMAG Pharmaceuticals, Inc.
Kristen Galfetti
617-498-3362

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark: